Lakvinimod

Lakvinimod
	5-hloro-N-etil-4-hidroksi-1-metil-2-okso-; N-fenil-1,2-dihidrohinolin-3-karboksamid
Identifikacija
CAS registarski broj	248282-07-7
PubChem	216469
Jmol-3D slike	Slika 1
SMILES
	CCN(c1ccccc1)C(=O)C\3=C(/O)c2c(Cl)cccc2N(C)C/3=O
Svojstva
Molekulska formula	C19H17ClN2O3
Molarna masa	356.803 g/mol
	; ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

Lakvinimod (Laquinimod) je eksperimentalni imunomodulator koji su razvile kompanije Active Biotech i Teva. On se trenutno istražuje kao oralni tretman za multiplu sklerozu (MS).

Laquinimod je zamena za neuspešni eksperimentalni imunomodulator linomid kompanije Active Biotech.^[3]

Klinička ispitivanja

Ovo jedinjenje je bilo studirano u dva klinička ispitivanja faze II koristeći sukcesivne magnetno rezonantne snimke (MRI). Laquinimod izgleda da može da umanji aktivnost MS bolesti.^[4]^[5] Međutim, respons na datu dozu je bio protivrečan između nalaza ove dve studije.^[6]

Ispitivanje faze III je počelo 2008 godine.

Povezano

Multipla skleroza

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Tan IL, Lycklama à Nijeholt GJ, Polman CH et al (April 2000). „Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials”. Mult Scler 6 (2): 99–104. PMID 10773855.
↑ Comi G, Pulizzi A, Rovaris M, et al (June 2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet 371 (9630): 2085–92. DOI:10.1016/S0140-6736(08)60918-6. PMID 18572078.
↑ Polman C, Barkhof F, Sandberg-Wollheim M et al (March 2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology 64 (6): 987–91. DOI:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.
↑ Keegan BM, Weinshenker BG (June 2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet 371 (9630): 2059–60. DOI:10.1016/S0140-6736(08)60894-6. PMID 18572062.

Vanjske veze

Portal Hemija

Podaci u NIH registru studija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Tan IL, Lycklama à Nijeholt GJ, Polman CH et al (April 2000). „Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials”. Mult Scler 6 (2): 99–104. PMID 10773855.

[pmid18572078-4] Comi G, Pulizzi A, Rovaris M, et al (June 2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet 371 (9630): 2085–92. DOI:10.1016/S0140-6736(08)60918-6. PMID 18572078.

[pmid15781813-5] Polman C, Barkhof F, Sandberg-Wollheim M et al (March 2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology 64 (6): 987–91. DOI:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.

[6] Keegan BM, Weinshenker BG (June 2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet 371 (9630): 2059–60. DOI:10.1016/S0140-6736(08)60894-6. PMID 18572062.

[1]

[2]

[3]

[4]

[5]

[6]